=
Note: Conversion is based on the latest values and formulas.
Pharma Faces $236 Billion Patent Cliff by 2030: Key Drugs and … 7 Mar 2025 · Key therapeutic areas include oncology, type 2 diabetes, COPD, HIV, and lung cancer. Oncology, currently 22% of global drug revenue and projected to reach 27% by 2030, …
New Modalities & More Upsides in the Oncology Drug Market 5 Jun 2025 · New modalities, ADCs and bispecific antibodies, accounted for $18 billion in cancer medicine spending in 2024 and are fast-growing on a pipeline basis. What else stands out in …
Top oncology challenges in pharma | Within3 13 Apr 2023 · However, fierce competition will be just one of the top oncology challenges in pharma over the next several years. What else will the industry face? And what can oncology …
Just How Steep Is the Drug Patent Cliff? Ask These Pharmas 19 Mar 2025 · Merck’s Keytruda, for example, is far and away the best-selling drug on the planet at the moment, clocking in at nearly $30 billion in worldwide sales in 2024, but will go off …
White Paper Achieving Oncology Launch Excellence Fuelling this growth is a rich pipeline, with oncology trials representing 44% of total global R&D activity.3 Novel oncology modalities, especially cell and gene therapies, antibody drug …
Oncology drug launch success elements | McKinsey 2 Aug 2018 · Our experience shows that companies who launch oncology drugs successfully excel in four areas: Agility, speed, and competitive mind-set: They operate in an agile …
Strategies for Navigating the Pharma Patent Cliff: Insights from ... 5 Nov 2024 · “Companies are actively looking at ways to make their patents more robust, especially in the face of challenges from competitors,” Noor said. This includes tweaking …
15 Biologics are Going Off Patent (2025–2029) - clival.com 12 Jun 2025 · Now, a growing number of these high-value drugs are approaching patent expiry. Between 2025 and 2029, over a dozen blockbuster biologics will lose exclusivity—opening the …
Trends and Challenges in the Oncology Space - Biotech Connection 1 Aug 2018 · The product life cycle for oncology medicines is now almost five times shorter than it was in the 1990, with pipeline competitors existing for 80 percent of compounds being …
First-in-class versus best-in-class: an update for new market In 2020, two new drugs launched at nearly the same time in a breakthrough mecha-nistic class. The first was selpercatinib (Retevmo; Eli Lilly), a RET kinase inhibitor supported by strong...